CINA-LVO

Avicenna.AI

The CINA-LVO solution is designed to automatically detect and prioritize acute large vessel occlusions on CTA.
Product specifications Information source: Vendor
Last updated: Nov. 21, 2022
General
Product name CINA-LVO
Company Avicenna.AI
Subspeciality Neuro
Modality CT
Disease targeted Stroke
Key-features Large vessel occlusion detection, notification
Suggested use Before: adapting worklist order, flagging acute findings
Data characteristics
Population Suspicion of stroke
Input Brain CTA
Input format DICOM
Output bounding box, worklist order, notification
Output format DICOM SC, GSPS
Technology
Integration Integration in standard reading environment (PACS), Integration via AI marketplace or distribution platform
Deployment Locally on dedicated hardware, Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis Automatically, right after the image acquisition
Processing time 10 - 60 seconds
Certification
CE
Certified, Class I , MDD
FDA
 510(k) cleared, Class II
Market presence
On market since 02-2020
Distribution channels Eureka Clinical AI, Canon Automation Platform, Blackford, Arterys, Nuance AI Marketplace, Sectra Amplifier Store, deepcOS, Incepto, CARPL.ai
Countries present (clinical, non-research use)
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing
Pricing model Pay-per-use, Subscription
Based on Number of installations, Number of analyses
Evidence
Peer reviewed papers on performance

  • Validation of an artificial intelligence-driven large vessel occlusion detection algorithm for acute ischemic stroke patients (read)

  • Validation of a Deep Learning Tool in the Detection of Intracranial Hemorrhage and Large Vessel Occlusion (read)
Non-peer reviewed papers on performance
Other relevant papers